Hemoglobin A1c (HbA1c) levels prior to radical prostatectomy (RP) may predict tumor aggressiveness in prostate cancer patients with diabetes, Korean researchers reported in The Prostate (2009;69:820-826).
They reviewed data on 740 patients who underwent RP for clinically localized prostate cancer.
Among the 89 diabetic patients, those with a preoperative HbA1c level of 6.5% or higher had significantly increased rates of extraprostatic extension and pathologic Gleason scores of 7 or above compared with those whose HbA1c level was below 6.5%.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.